» Articles » PMID: 15542733

Study of Association Between Alpha-synuclein Gene Polymorphism and Methamphetamine Psychosis/dependence

Overview
Specialty Science
Date 2004 Nov 16
PMID 15542733
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Methamphetamine (MAP) dissipates proton gradients across the membranes of synaptic vesicles, enhances cytoplasmic dopamine (DA) concentrations, and causes calcium-independent, nonvesicular DA release into synapses. MAP is taken into the cytosol by the dopamine transporter (DAT) on the synaptic terminals of DA neurons, and endogenous DA is concurrently released through the transporter by carrier exchange mechanisms, resulting in a robust increase in DA concentration in the synaptic clefts. The enhanced DA release through DAT by MAP is the main mechanism for the reinforcing effects of MAP. The complexes of alpha-synuclein and DAT facilitate membrane clustering of the DAT, thereby accelerating DA uptake in vitro. alpha-Synuclein has been shown to be overexpressed in the midbrain DA neurons of chronic cocaine abusers. The present study was performed to study the association between the alpha-synuclein gene polymorphisms and MAP psychosis/dependence in Japanese population. Since the T10A7 polymorphic site at the 5' end of the noncoding exon 1' in the alpha-synuclein gene is highly polymorphic, we analyzed the noncoding exon 1' and intron 1, including this polymorphic site by sequencing. We confirmed four single nucleotide polymorphisms (SNPs) within 1.38 kbp of the T10A7 polymorphic site. No significant difference was found in genotype or allele frequencies in the T10A7 polymorphic site between MAP psychotic/dependent and control subjects. We found significant association between three SNPs in the vicinity of this polymorphic site in intron 1 and MAP psychosis/dependence in female subjects, but not in males. These results suggest an association of the alpha-synuclein gene polymorphisms with MAP psychosis/dependence in our female subjects. Further analyses are necessary to clarify the gender difference, by using a larger sample size and/or different ethnic groups, as well as functional variations in the alpha-synuclein gene.

Citing Articles

Modeling methamphetamine use disorder in mammals: Sex differences in behavioral, biochemical, and transcriptional consequences.

Daiwile A, Cadet J Adv Pharmacol. 2024; 99:145-168.

PMID: 38467480 PMC: 11474929. DOI: 10.1016/bs.apha.2023.08.002.


Sex differences in methamphetamine use disorder perused from pre-clinical and clinical studies: Potential therapeutic impacts.

Daiwile A, Jayanthi S, Cadet J Neurosci Biobehav Rev. 2022; 137:104674.

PMID: 35452744 PMC: 9119944. DOI: 10.1016/j.neubiorev.2022.104674.


Methamphetamine use alters human plasma extracellular vesicles and their microRNA cargo: An exploratory study.

Sandau U, Duggan E, Shi X, Smith S, Huckans M, Schutzer W J Extracell Vesicles. 2021; 10(1):e12028.

PMID: 33613872 PMC: 7890470. DOI: 10.1002/jev2.12028.


Genetics of methamphetamine use disorder: A systematic review and meta-analyses of gene association studies.

Guerin A, Nestler E, Berk M, Lawrence A, Rossell S, Kim J Neurosci Biobehav Rev. 2020; 120:48-74.

PMID: 33217458 PMC: 7856253. DOI: 10.1016/j.neubiorev.2020.11.001.


mTOR-Related Brain Dysfunctions in Neuropsychiatric Disorders.

Ryskalin L, Limanaqi F, Frati A, Busceti C, Fornai F Int J Mol Sci. 2018; 19(8).

PMID: 30061532 PMC: 6121884. DOI: 10.3390/ijms19082226.